There are currently no Publications
Déclion has been granted US. Patent Number 8.378,072 titled "Methods for Designing and Synthesizing Directed Sequence Polymer Compositions via the Directed Expansion of Epitope Permeability" which provides broad patent protection for the Company's DEEP platform. The DEEP platform, or the Directed Expansion of Epitope Permutation, forms the basis of Déclion's declensional peptides.
Thomas P. Mathers, Chairman and Chief Executive Officer, will present a corporate update at the BIO Investor Forum 2012 in San Francisco, CA. Mr. Mathers’ presentation is scheduled for Tuesday, October 9, 2012 at 2:00 p.m. in the Marina Room at the Palace Hotel. Mr. Mathers will also announce a new project financing capitalizing the development of two new disease modifying ModuloDEEP declensional peptides for treating Parkinson’s disease and tauopathies such as progressive supranuclear palsy (PSP), mild cognitive impairment (MCI) and Alzheimer’s disease (AD).
There is currently no Media Coverage